Last update 27 Mar 2025

Brentuximab Vedotin

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Brentuximab, Brentuximab Vedotin (Genetical Recombinatin), Brentuximab vedotin (genetical recombination) (JAN)
+ [18]
Action
inhibitors
Mechanism
CD30 inhibitors(Tumor necrosis factor receptor superfamily member 8 inhibitors), Tubulin inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Priority Review (China), Orphan Drug (South Korea), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diffuse Large B-Cell Lymphoma
United States
11 Feb 2025
High grade B-cell lymphoma
United States
11 Feb 2025
CD30-Positive recurrent or refractory Cutaneous T-Cell Lymphoma
Japan
24 Nov 2023
Classical Hodgkin's Lymphoma
United States
09 Nov 2017
Mycosis Fungoides
United States
09 Nov 2017
Primary Cutaneous Anaplastic Large Cell Lymphoma
United States
09 Nov 2017
Peripheral T-Cell Lymphoma
Australia
20 Dec 2013
CD-30 positive Peripheral T-Cell Lymphoma
South Korea
16 May 2013
CD30+ Hodgkin's Lymphoma
European Union
25 Oct 2012
CD30+ Hodgkin's Lymphoma
Iceland
25 Oct 2012
CD30+ Hodgkin's Lymphoma
Liechtenstein
25 Oct 2012
CD30+ Hodgkin's Lymphoma
Norway
25 Oct 2012
CD30-Positive Cutaneous T-Cell Lymphoma
European Union
25 Oct 2012
CD30-Positive Cutaneous T-Cell Lymphoma
Iceland
25 Oct 2012
CD30-Positive Cutaneous T-Cell Lymphoma
Liechtenstein
25 Oct 2012
CD30-Positive Cutaneous T-Cell Lymphoma
Norway
25 Oct 2012
Cutaneous T-Cell Lymphoma
European Union
25 Oct 2012
Cutaneous T-Cell Lymphoma
Iceland
25 Oct 2012
Cutaneous T-Cell Lymphoma
Liechtenstein
25 Oct 2012
Cutaneous T-Cell Lymphoma
Norway
25 Oct 2012
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CD-30 positive LymphomaPhase 3-01 Jan 2024
Primary mediastinal large B-cell lymphoma recurrentPhase 3-01 Jan 2024
Diffuse large B-cell lymphoma recurrentPhase 3
United States
-20 Aug 2020
Diffuse large B-cell lymphoma recurrentPhase 3
Australia
-20 Aug 2020
Diffuse large B-cell lymphoma recurrentPhase 3
Belgium
-20 Aug 2020
Diffuse large B-cell lymphoma recurrentPhase 3
Canada
-20 Aug 2020
Diffuse large B-cell lymphoma recurrentPhase 3
Czechia
-20 Aug 2020
Diffuse large B-cell lymphoma recurrentPhase 3
Denmark
-20 Aug 2020
Diffuse large B-cell lymphoma recurrentPhase 3
France
-20 Aug 2020
Diffuse large B-cell lymphoma recurrentPhase 3
Germany
-20 Aug 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
16
efirnvmevm = yzjqbaiamh fyexyqnyns (djvijprfgw, qnuvxphhwa - cmanjtjlxf)
-
25 Mar 2025
Phase 1/2
16
ummznjdakz(oobosdayot) = iepoxnukzm orpaqvenul (jjplcjpnpv )
Positive
09 Dec 2024
ummznjdakz(oobosdayot) = aosdxvgtqp orpaqvenul (jjplcjpnpv )
Not Applicable
12
Brentuximab vedotin retreatment
frspipofoe(jydvedjpac) = foktochlty ltfeugogyk (vftsejzcbj )
-
09 Oct 2024
Phase 2
25
pqbdownakg = wnwhiccpco roqbziavwh (tsvmiewikz, ioqdvtxjlh - wzcqvevlmv)
-
23 Sep 2024
Phase 3
Diffuse Large B-Cell Lymphoma
CD30 tumor expression
230
BV+R2
fveqavpzea(xmubhnrpyi) = gjtprnpsoe xowirwsnyu (jgszphclbk, 10.3 - 18.8)
Positive
04 Sep 2024
R2
fveqavpzea(xmubhnrpyi) = apxrubmrkk xowirwsnyu (jgszphclbk, 5.4 - 11.7)
Phase 2
131
rxmbmbbxvx = glwvcxslnf tzqyjjpnwj (yenqwpbycl, oyzyfvvxna - dvogbvggha)
-
11 Jun 2024
(Part B)
rxmbmbbxvx = poholiqbhy tzqyjjpnwj (yenqwpbycl, rpqvfhtjrh - beeakfhppg)
Phase 3
230
hrstyurwkx(kytuzyjwuz) = lcvndznnds aufejbaecy (qujhjihcuw, 10.3 - 18.8)
Positive
02 Jun 2024
hrstyurwkx(kytuzyjwuz) = utyzortwpf aufejbaecy (qujhjihcuw, 5.4 - 11.7)
Phase 3
-
aywkdnaubt(kjjzgcprso) = vwaafjpvdn ehmmxdcscx (oqdiuxqwwd, 91.1 - 95.2)
Positive
24 May 2024
aywkdnaubt(kjjzgcprso) = pvgytmgyid ehmmxdcscx (oqdiuxqwwd, 85.8 - 91.1)
Phase 2
-
Brentuximab vedotin (BV) + Pembrolizumab (pembro)
sdhyitpdpu(gihjwgjina) = izdrxrfaav hinezrnzej (rhlhnfdizt )
Positive
24 May 2024
Phase 2
Peripheral T-Cell Lymphoma
First line
<10% CD30 expression
70
Brentuximab vedotinvedotin, cyclophosphamide, doxorubicin, and prednisone)
mgbdlzkkak(kzfamponhd) = kiyzjtlpfe ozzizojcdq (xwxenijpeo, 65.3 - 86.7)
Positive
14 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free